Welcome to our dedicated page for NOVONIX SEC filings (Ticker: NVNXF), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
NOVONIX Limited filings document foreign-issuer reports furnished on Form 6-K, with exhibits drawn from ASX announcements and corporate notices. The record includes disclosures on annual general meeting presentations and voting results, material-event updates, material agreements, operating and financial results, and governance matters tied to the company's battery materials business.
Capital-structure filings cover applications for quotation of ordinary fully paid securities, securities issued from option exercises or convertible-security conversions, performance rights, and director interest notices. These filings also record shareholder voting matters and formal updates relevant to NOVONIX's ADR and foreign-issuer reporting framework.
NOVONIX Ltd (NVX) has entered into a strategic partnership memorandum of understanding with ACP Technologies, LLC to advance a fully domestic anode material supply chain for the North American battery industry. The non-binding MOU provides a framework to pursue collaborative projects and negotiate definitive agreements.
The collaboration combines ACPT’s proprietary processes for converting petroleum-derived feedstocks into engineered carbon precursors with NOVONIX’s expertise in synthetic graphite anode active materials, including pitch coated synthetic graphite for high-performance and fast-charging applications. Materials from the partnership are expected to support process validation, customer sampling, and qualification of new domestic feedstocks, although there is no assurance that definitive agreements or specific projects will proceed.
NOVONIX Limited (NVX) reports that a share price breach of the A$0.12 Floor Price under its funding agreement with YA II PN, Ltd has triggered an Amortisation Event. With US$35,000,000 outstanding under the convertible debenture facility, NOVONIX must pay US$7,000,000 in cash by September 21, 2026, reducing the outstanding amount to US$28,000,000. The company plans to fund this from existing cash, and additional 30‑day rolling amortisation payments may be required if the event continues.
Separately, NOVONIX reports progress with its lead customer: an initial mass production qualification C-sample of synthetic graphite anode active material met 12 of 14 specifications, with one unmet parameter within about 1% of the requirement. NOVONIX expects mass production sales to this customer to begin in the second half of 2027, subject to successful qualification.
Novonix Limited reports the issue of 171,591 new ordinary fully paid shares (ASX code NVX) following the exercise or conversion of performance rights under an employee incentive scheme. These new shares are additional securities in an existing quoted class and are intended to be quoted on ASX.
The shares are being issued for non-cash consideration, with the value per security estimated at AUD 0.150000. After quotation, total quoted ordinary shares will be 997,784,585, alongside several unquoted classes including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Limited is changing the ratio of its American Depositary Shares so that the current ratio of 1 ADS representing 4 ordinary shares will become 1 ADS representing 40 ordinary shares. This has the same effect as a one-for-ten reverse split of existing ADSs, with each 10 existing ADSs exchanged for 1 new ADS. The new ADS ratio is expected to become effective on 27 August 2026, and the ADSs will continue trading on Nasdaq under the ticker NVX. The change does not alter the number of NOVONIX ordinary shares on issue or affect the ordinary shares listed on the ASX. NOVONIX previously received notice that its ADSs were below Nasdaq’s US$1.00 minimum bid price for 30 consecutive business days and was given 180 calendar days to regain compliance. The ADS ratio change is intended to increase the per-ADS trading price and assist in regaining compliance, though there is no assurance this will occur.
NOVONIX Limited reported quarterly operational and cash flow details while progressing its strategic graphite anode active material business. The company delivered a mass-production C-sample of synthetic graphite AAM to Panasonic Energy, with internal testing indicating it meets specifications, and reaffirmed its target to begin mass production for Panasonic in the second half of 2027, subject to completion of qualification. It completed an institutional placement of A$20.7 million and raised A$0.96 million via a share purchase plan, and the U.S. Government certified the Riverside project in connection with a previously allocated US$103 million Section 48C tax credit. NOVONIX also closed the divestiture of its Battery Technology Solutions division.
For the quarter ended 30 June 2026, net cash used in operating activities was 8,642 $USD’000 and investing outflows were 2,441 $USD’000, while financing activities provided 13,226 $USD’000. Cash and cash equivalents were US$59.5 million, with estimated funding capacity of 6.9 quarters. Capital expenditures totaled 2,260 $USD’000, mainly for the Riverside facility, and related-party payments were US$281,000. The company has fully drawn US$40,000,000 in unsecured convertible debentures and a USD$30,100,000 real estate facility.
NOVONIX Ltd director Sharan Burrow reported acquiring 31,250 ordinary shares on 2026-07-22 in an "other" acquisition (transaction code J) at $0.16 per share. Following this transaction, Burrow directly holds 246,989 ordinary shares. The Rule 10b5-1 trading-plan checkbox is not marked.
NOVONIX Limited completed a Share Purchase Plan, issuing 6,016,250 fully paid ordinary shares at A$0.16 each to raise A$962,600 before costs. The offer, which closed on 17 July 2026, allowed eligible shareholders to apply for up to A$30,000 of new shares.
The company plans to use the proceeds to fund capital expenditure to support production capacity and forecast customer demand. Valid applications were received from approximately 89 eligible shareholders, with an average application of approximately A$10,816 and a participation rate of approximately 0.3% of eligible shareholders.
The 6,016,250 new SPP Shares represent approximately 0.6% of NOVONIX’s ordinary shares on issue. Following quotation, total ordinary fully paid shares quoted on ASX are 997,612,994.
NOVONIX Limited reports that the ASX has granted waivers from Listing Rules 7.1 and 10.11 for its Share Purchase Plan. These waivers allow NOVONIX to issue new SPP shares at an offer price of $0.16 per share without prior shareholder approval and without using its standard placement capacity.
The offer price is the same as the institutional placement completed earlier and represents a discount of about 31.2% to the 5-day VWAP calculated to 15 June 2026. The company expects overall dilution from the SPP to be approximately 2.17%, with SPP shares capped at no more than 30% of existing fully paid ordinary shares.
The SPP timetable runs from a record date on 16 June 2026, opens on 22 June 2026, closes on 14 August 2026, with allotment on or about 19 August 2026 and trading of SPP shares expected to commence on or about 20 August 2026.
NOVONIX LIMITED has applied to quote 34,824 additional ordinary fully paid shares on the ASX, issued on July 3, 2026 after performance rights were converted under an employee incentive scheme. These new shares are valued at an estimated AUD 0.155 per security and rank equally with existing shares.
Following this small non-cash issuance, the company’s total quoted ordinary share capital will comprise 991,596,744 NVX ordinary fully paid shares. NOVONIX also has several classes of unquoted securities on issue, including performance rights, options, share rights, convertible notes and convertible debentures.
NOVONIX Ltd Chief Financial Officer Robert Buell Long reported internal changes to his equity awards involving performance rights. On June 30, 2026, three transactions coded as “J” (Other acquisition or disposition) affected a total of 4,576,670 performance rights tied to ordinary shares, all at a reported price of $0.00 per right. Each line shows zero performance rights remaining of that series following the transactions, and no ordinary share purchases or sales were reported.